The local anesthesia drugs market size in Europe is estimated to be valued at USD 1.27 billion by 2028 from USD 0.93 billion in 2023, growing at a CAGR of 6.51% from 2023 to 2028.
The increasing number of surgeries across the European region drives the growth of the Europe local anesthesia drugs market. The high prevalence of chronic diseases such as cancer, cardiovascular disease, and arthritis necessitates a greater volume of surgical interventions in Europe. Recent surveys indicate that approximately 35% of the population in Europe suffers from chronic diseases. Surgeries play a crucial role in the treatment of these conditions. Local anesthesia drugs are specifically designed to create numbness in targeted areas of the body, ensuring patients do not experience pain during surgical procedures. Healthcare specialists administer these drugs through syringes by injecting them into the skin. In open heart surgeries, local anesthetics are employed to minimize pain when healthcare providers make incisions near the heart for procedures such as balloon angioplasty or stent placement aimed at reducing the risk of heart attack and other heart-related issues.
The growing utilization of these drugs in postoperative pain management further fuels the growth rate of the Europe local anesthesia drugs market. Following surgical procedures, many individuals experience significant pain after being discharged from the intensive care unit (ICU). Healthcare providers administer anesthesia drugs to patients post-surgery to alleviate pain during specific periods. The increasing geriatric population in Europe contributes to the regional market growth. The elderly population is particularly sensitive during the treatment process, and unexpected complications may arise. Anesthesia care plays a crucial role in mitigating these complications and improving treatment outcomes.
The growing number of advancements in developing novel drugs with improved safety profiles and minimizing side effects contribute to the growth of the Europe local anesthesia drugs market. The manufacturing of specialized devices for anesthesia drug development drives the European market growth. Researchers are actively working on developing anesthesia drugs tailored to different age groups. The growing research and development efforts, rising support and the involvement of public and private healthcare organizations further boost the European market growth.
The presence of side effects associated with these drugs, including headache, blurred vision, shivering, weakness and urinary problems primarily hamper the European market growth. The shortage of skilled healthcare providers, stringent government regulations and inadequate infrastructure facilities further hinder the growth of the European market.
This research report on the Europe local anesthesia drugs market has been segmented and sub-segmented into the following categories.
By Drug Type:
By Application:
By Country:
The Europe region occupied the second biggest share of the worldwide market in 2022 and is predicted to witness a healthy CAGR during the forecast period owing to factors such as a rising patient population, advancements in treatment processes, rising healthcare expenditure, the measures implemented by the European governments and healthcare organizations to facilitate the approval of local anesthesia drugs.
Germany led the local anesthesia drugs market in the European region in 2022 and is estimated to grow at a healthy CAGR during the forecast period. Approximately 80% of Germans experiencing oral issues seek treatment at dental clinics. Local anesthesia is widely employed by healthcare providers in the treatment of dental diseases such as tooth decay, gum disease, tooth discoloration, and bad breath.
The UK market is another noteworthy regional market for local anesthesia drugs in Europe and is anticipated to witness a healthy CAGR during the forecast period owing to the rapid adoption of anesthesia drugs in numerous hospitals for medical purposes. The presence of pharmaceutical companies manufacturing anesthesia drugs for diverse applications further supports the UK market growth. The growing number of clinical trial centers and the presence of key players in the UK further fuels the UK market growth.
KEY MARKET PLAYERS:
AstraZeneca plc, Fresenius SE & Co. KGaA, Novartis AG, GlaxoSmithKline plc and Johnson & Johnson are some of the noteworthy companies in the European local anesthesia drugs market.
Frequently Asked Questions
AstraZeneca plc, Fresenius SE & Co. KGaA, Novartis AG, GlaxoSmithKline plc and Johnson & Johnson are some of the major players in the europe local anesthesia drugs market.
The growth rate of the europe local anesthesia drugs market is 6.51% during the forecast period.
The europe local anesthesia drugs market size is projected to reach USD1.27 billion by 2028.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region